# Johnson & Johnson

Type: Company

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/johnson-johnson
Canonical HTML page: https://gethealthbrief.com/entity/johnson-johnson

## Timeline

- **2026-Q4**: Data Readout — Anticipated top-line data from the Phase 3 VERIFY clinical trial.
- **2026-03-18**: Q4 Earnings — Scheduled announcement of quarterly financial results and pipeline update.
- **2025-01-10**: VERIFY Enrollment — Completion of enrollment for the Phase 3 trial of rusfertide in polycythemia vera.
- **2024-05-15**: J&J Milestone — Protagonist receives $231M milestone payment for icotrokinra progress.

## Recent coverage (7 stories)

### J&J's $5.5B Talc Payout: Ovarian Cancer Claims and Consumer Safety Shift
2026-07-28 14:40:04 · Sentiment: Bearish · Impact: 7/10 · Sources: 3

The settlement highlights decades of health concerns over talc's link to ovarian cancer, prompting J&J to switch to cornstarch and underscoring ongoing consumer trust issues.
Full story: https://gethealthbrief.com/story/jnj-talc-cancer-settlement-health-impact

### Over 500 Tylenol suits revived: Prenatal care guidelines under microscope
2026-07-25 19:57:02 · Sentiment: Bearish · Impact: 7/10 · Sources: 2

The legal reinstatement of Tylenol-autism lawsuits pressures healthcare providers to reconcile conflicting evidence on acetaminophen safety in pregnancy, potentially altering clinical guidance, patient counseling, and EHR decision support.
Full story: https://gethealthbrief.com/story/tylenol-autism-lawsuits-revived-health

### J&J’s $100B Revenue Runway: How Next-Gen Drugs Are Plugging the Stelara Gap
2026-07-20 00:11:51 · Sentiment: Bullish · Impact: 7/10 · Sources: 2

J&J’s Q2 2026 earnings beat underscores a successful pivot away from Stelara’s $10B peak. New oncology and immunology drugs are powering growth, with full-year revenue now expected to top $100B. For healthcare stakeholders, this signals pipeline resilience and a defensive stock offering amid sector headwinds.
Full story: https://gethealthbrief.com/story/jnj-100b-pharma-pipeline-stelara-gap-health

### Protagonist Therapeutics Eyes Pivotal Q4 Results Amid Oral Peptide Expansion
2026-03-17 07:33:05 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Protagonist Therapeutics (PTGX) is scheduled to release its quarterly earnings on Wednesday, March 18, 2026, with investors focused on the commercialization path for rusfertide and the Phase 3 progress of its oral IL-23 receptor antagonist, icotrokinra. The results will provide a critical update on the company's transition from a clinical-stage biotech to a potential commercial powerhouse in the immunology and hematology sectors.
Full story: https://gethealthbrief.com/story/protagonist-therapeutics-q4-earnings-preview-2026

### BofA Lifts Johnson & Johnson Price Target on Robust Pipeline Momentum
2026-03-12 08:11:39 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Bank of America has raised its price target for Johnson & Johnson (JNJ), citing a strengthened outlook for the company's pharmaceutical and MedTech pipelines. The upgrade reflects growing investor confidence in JNJ's post-Kenvue strategy, which prioritizes high-margin innovation in oncology, immunology, and surgical robotics.
Full story: https://gethealthbrief.com/story/bofa-raises-jnj-price-target-pipeline-growth

### Global Minimally Invasive Surgical Market Set for 7% CAGR Through 2034
2026-03-11 23:18:20 · Sentiment: Bullish · Impact: 6/10 · Sources: 2

A new DelveInsight report projects a steady 7% CAGR for the minimally invasive surgical devices (MISD) market through 2034, driven by technological leaps in robotics and a global shift toward outpatient care. This expansion reflects a broader healthcare transition prioritizing reduced recovery times and improved clinical outcomes over traditional open surgeries.
Full story: https://gethealthbrief.com/story/minimally-invasive-surgical-market-growth-2034

### Scientific Studies Rebut RFK Jr. Claims on Vaccines and Pharmaceuticals
2026-02-25 12:41:21 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

A series of recent clinical studies have directly challenged the public health assertions made by Robert F. Kennedy Jr. regarding vaccines, Tylenol, and antidepressants. These findings underscore a growing tension between evidence-based medicine and the policy platform of the potential future leadership at the Department of Health and Human Services.
Full story: https://gethealthbrief.com/story/studies-challenge-rfk-vaccine-tylenol-claims

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.